1-3 of 3
Susanne Schreiber
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma

Kathleen Schwarz, MD, Wagner Julia, MD, Susanne Schreiber, MD, Burkhard Schmidt, MD, Alexander Hoellein, MD, Mareike Verbeek, MD, Markus Schwaiger, MD, Christian Peschel, MD, Klemens Scheidhauer, MD, Christoph von Schilling, MD, Ulrich Keller, MD
Journal: Blood
Blood (2012) 120 (21): 3700.
https://doi.org/10.1182/blood.V120.21.3700.3700
Published: 2012
Journal Articles

Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response

Carole Bourquin, Laura Schmidt, Veit Hornung, Cornelia Wurzenberger, David Anz, Nadja Sandholzer, Susanne Schreiber, Andreas Voelkl, Gunther Hartmann, Stefan Endres
Journal: Blood
Blood (2006) 109 (7): 2953–2960.
https://doi.org/10.1182/blood-2006-07-033258
Published: 2006
Journal Articles

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

Niklas Zojer, Robert Königsberg, Jutta Ackermann, Elke Fritz, Susanne Dallinger, Elisabeth Krömer, Hannes Kaufmann, Lucia Riedl, Heinz Gisslinger, Susanne Schreiber, Renate Heinz, Heinz Ludwig, Heinz Huber, Johannes Drach
Journal: Blood
Blood (2000) 95 (6): 1925–1930.
https://doi.org/10.1182/blood.V95.6.1925
Published: 2000